 |
|
|
| |
Hepatitis B virus antigen reduction effect of RO7049389 plus NUC
with/without Peg-IFN in chronic hepatitis B patients
|
| |
| |
EASL 2022 June 22-26 London
Jinlin HOU1, Edward J GANE2, Wenhong ZHANG3, Jiming ZHANG3, Man-Fung YUEN4, Tien Huey LIM5, Rozalina BALABANSKA6, Qing XIE7, Piyawat KOMOLMIT8, Xieer LIANG1, Wen ZHANG9, Xue ZHOU9, Zenghui XUE10, Miriam TRIYATNI11, Ethan CHEN10, Yuchen ZHANG9, Qingyan BO10
1Nanfang Hospital, Southern Medical University, Guangzhou, China; 2New Zealand Liver Transplant Unit, The University of Auckland, Auckland, New Zealand; 3Huashan Hospital, Fudan University, Shanghai, China; 4Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; 5Middlemore Hospital, Auckland, New Zealand; 6Acibadem City Clinic Tokuda Hospital EAD, Sofia, Bulgaria; 7Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; 8King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 9Roche Pharma Research and Early Development, Roche Innovation Centre Shanghai, Shanghai, China; 10Roche (China) Holding, Shanghai, China; 11F. Hoffmann-La Roche, Basel, Switzerland
|
| |
|
|
|
|
|
